RAD23B and breast cancer: In that work, patients in the low-CRG score group were characterized by higher immune cell infiltration, immune checkpoint expression, immune checkpoint inhibitor scores, and greater sensitivity to immunotherapy; and they found that RAD23B was a favorable target associated with BC progression, drug resistance, and poor prognosis.